Patent awarded for anthrax infection inhibitor

Omni Bio Pharmaceutical, Inc., has been awarded a patent titled “Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections” that may be able to inhibit anthrax infection.

This new patent is comprised of technology licensed to Omni Bio Pharmaceutical, Inc., by the University of Colorado - Denver and covers the inhibitions of all forms of Bacillus anthracis infection, also known as anthrax. The novel approach to preventing bacteria uses four new peptides made of up to 10 linked amino acids that prevent the infective components of anthrax from entering a cell.

“The issuance of this patent by the USPTO expands our proprietary technology platform and is an important milestone in developing innovative therapies to address potentially large and underserved markets,” Dr. Charles A. Dinarello, the acting CEO of Omni Bio Pharmaceutical, Inc., said. “The focus of this patent demonstrates that AAT and AAT related peptides may have the potential to address a variety of indications, such as the prevention and treatment of anthrax infection, and may open proprietary channels of opportunity for the development of new therapeutics and preventatives in a variety of areas including bacterial infection and biohazards.”

The patent, issued by the U.S. Patent and Trademark Office on December 14, was No. 7,850,970.

Omni Bio Pharmaceutical, Inc., will have a presentation at the Biotech Showcase 2011 in San Francisco in January 11 at 11:45 a.m.